Hesperetin suppresses LPS/high glucose-induced inflammatory responses via TLR/MyD88/NF-κB signaling pathways in THP-1 cells

Aeri Lee; HyunJi Gu; Min-Hee Gwon; Jung-Mi Yun

doi:10.4162/nrp.2021.15.5.591

Hesperetin suppresses LPS/high glucose-induced inflammatory responses via TLR/MyD88/NF-κB signaling pathways in THP-1 cells

Nutr Res Pract. 2021 Oct;15(5):591-603. doi: 10.4162/nrp.2021.15.5.591. Epub 2021 May 4.

Authors

Aeri Lee¹, HyunJi Gu¹, Min-Hee Gwon², Jung-Mi Yun¹

Affiliations

¹ Department of Food and Nutrition, Chonnam National University, Gwangju 61186, Korea.
² Department of Education, Graduate School of Education, Chonnam National University, Gwangju 61186, Korea.

Abstract

Background/objectives: Unregulated inflammatory responses caused by hyperglycemia may induce diabetes complications. Hesperetin, a bioflavonoid, is a glycoside in citrus fruits and is known to have antioxidant and anticarcinogenic properties. However, the effect of inflammation on the diabetic environment has not been reported to date. In this study, we investigated the effect of hesperetin on proinflammatory cytokine secretion and its underlying mechanistic regulation in THP-1 macrophages with co-treatment LPS and hyperglycemic conditions.

Materials/methods: THP-1 cells differentiated by PMA (1 μM) were cultured for 48 h in the presence or absence of hesperetin under normoglycemic (5.5 mM/L glucose) or hyperglycemic (25 mM/L glucose) conditions and then treated with LPS (100 ng/mL) for 6 h before harvesting. Inflammation-related proteins and mRNA levels were evaluated by enzyme-linked immunosorbent assay, western blot, and quantitative polymerase chain reaction analyses.

Results: Hesperetin (0-100 μM, 48 h) treatment did not affect cell viability. The tumor necrosis factor-α and interleukin-6 levels increased in cells co-treated with LPS under hyperglycemic conditions compared to normoglycemic conditions, and these increases were decreased by hesperetin treatment. The TLR2/4 and MyD88 activity levels increased in cells co-treated with LPS under hyperglycemic conditions compared to normoglycemic conditions; however, hesperetin treatment inhibited the TLR2/4 and MyD88 activity increases. In addition, nuclear factor-κB (NF-κB) and Acetyl-NF-κB levels increased in response to treatment with LPS under hyperglycemic conditions compared to normoglycemic conditions, but those levels were decreased when treated with hesperetin. SIRT3 and SIRT6 expressions were increased by hesperetin treatment.

Conclusions: Our results suggest that hesperetin may be a potential agent for suppressing inflammation in diabetes.

Keywords: Diabetes mellitus; NF-kappa B; hesperetin; inflammation; macrophages.